Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Reviva Pharmaceuticals Holdings, Inc. disclosed a joint Schedule 13G filing showing a group of filers—Integrated Core Strategies (US) LLC, Millennium Management LLC, Millennium Group Management LLC and Israel A. Englander—each reporting 793,952 shares, representing 6.2% of the class.
The filing states these shares are held by entities over which Millennium Management LLC and related managers have voting control and investment discretion. The submission includes a Joint Filing Agreement dated March 27, 2026 and lists the issuer CUSIP 76152G209.
Insights
Joint disclosure shows coordinated reporting of a substantial passive stake (6.2%).
The Schedule 13G lists 793,952 shares (6.2%) held through entities subject to voting and investment discretion by Millennium Management LLC and affiliated managers. The report is styled as a joint filing with an executed Joint Filing Agreement dated March 27, 2026.
Reported shared voting and dispositive power indicate collective reporting rather than sole individual control. Subsequent filings or amendments could clarify any changes in ownership or voting arrangements.
Key Figures
Shares reported:793,952 sharesPercent of class:6.2%CUSIP:76152G209+2 more
5 metrics
Shares reported793,952 sharesAmount listed on cover pages for each filer
Percent of class6.2%Percent reported on each cover page
CUSIP76152G209Issuer identifier listed on the filing
Cover-page date03/23/2026Date shown near the top of the filing excerpt
Joint Filing Agreementdated March 27, 2026Exhibit I referenced and signatures dated March 27, 2026
"Joint Schedule 13G filing showing ownership and control"
A Schedule 13G is a formal document that investors file with the government when they acquire a large ownership stake in a company, usually for investment purposes rather than control. It helps keep the public informed about who owns significant parts of a company's shares, which can influence how the company is managed and how investors make decisions. Filing this schedule is important for transparency and understanding the ownership landscape of publicly traded companies.
Joint Filing Agreementlegal
"Exhibit I: Joint Filing Agreement, dated as of March 27, 2026"
shared dispositive powerfinancial
"Shared Dispositive Power 793,952.00 listed on cover pages"
beneficially ownedregulatory
"Amount beneficially owned: See response to Item 9 on each cover page"
Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What stake did Millennium-affiliated filers report in RVPH?
They reported 793,952 shares, representing 6.2% of Reviva Pharmaceuticals' common stock, as shown on the Schedule 13G cover pages. The amount and percentage are listed directly on each cover page.
Who jointly filed the Schedule 13G for RVPH?
The joint filing parties are Integrated Core Strategies (US) LLC, Millennium Management LLC, Millennium Group Management LLC, and Israel A. Englander, per the Item 2 responses and the Joint Filing Agreement dated March 27, 2026.
What does shared voting and dispositive power mean in this filing?
The filing shows shared voting and dispositive power of 793,952 shares, indicating the reported shares are controlled collectively by entities with voting or investment discretion, as described under Item 4 explanations.
What identifier and dates are on the Schedule 13G for RVPH?
The issuer CUSIP is 76152G209 and the document shows a relevant date of 03/23/2026 on the cover and a Joint Filing Agreement dated March 27, 2026, per signature lines.
Does the Schedule 13G state sole beneficial ownership by any filer?
No. The cover-page entries list 0 for sole voting and sole dispositive power and show 793,952 for shared voting and dispositive power for each filer, per the cover-page fields.
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
UNDER THE SECURITIES EXCHANGE ACT OF 1934
Reviva Pharmaceuticals Holdings, Inc.
(Name of Issuer)
Common Stock, par value $0.0001 per share
(Title of Class of Securities)
76152G209
(CUSIP Number)
03/23/2026
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)
schemaVersion:
SCHEDULE 13G
CUSIP Number(s):
76152G209
1
Names of Reporting Persons
Integrated Core Strategies (US) LLC
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
793,952.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
793,952.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
793,952.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
6.2 %
12
Type of Reporting Person (See Instructions)
OO
SCHEDULE 13G
CUSIP Number(s):
76152G209
1
Names of Reporting Persons
Millennium Management LLC
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
793,952.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
793,952.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
793,952.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
6.2 %
12
Type of Reporting Person (See Instructions)
OO
SCHEDULE 13G
CUSIP Number(s):
76152G209
1
Names of Reporting Persons
Millennium Group Management LLC
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
793,952.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
793,952.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
793,952.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
6.2 %
12
Type of Reporting Person (See Instructions)
OO
SCHEDULE 13G
CUSIP Number(s):
76152G209
1
Names of Reporting Persons
Israel A. Englander
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
UNITED STATES
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
793,952.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
793,952.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
793,952.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
6.2 %
12
Type of Reporting Person (See Instructions)
IN
SCHEDULE 13G
Item 1.
(a)
Name of issuer:
Reviva Pharmaceuticals Holdings, Inc.
(b)
Address of issuer's principal executive offices:
10080 N. Wolfe Road, Suite SW3-200, Cupertino, California 95014
Item 2.
(a)
Name of person filing:
Integrated Core Strategies (US) LLC
Millennium Management LLC
Millennium Group Management LLC
Israel A. Englander
(b)
Address or principal business office or, if none, residence:
Integrated Core Strategies (US) LLC
c/o Millennium Management LLC
399 Park Avenue
New York, New York 10022
Millennium Management LLC
399 Park Avenue
New York, New York 10022
Millennium Group Management LLC
399 Park Avenue
New York, New York 10022
Israel A. Englander
c/o Millennium Management LLC
399 Park Avenue
New York, New York 10022
(c)
Citizenship:
Integrated Core Strategies (US) LLC - Delaware
Millennium Management LLC - Delaware
Millennium Group Management LLC - Delaware
Israel A. Englander - United States
(d)
Title of class of securities:
Common Stock, par value $0.0001 per share
(e)
CUSIP Number(s):
76152G209
Item 3.
If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)
Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)
Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)
Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)
Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)
An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)
An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)
A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)
A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)
A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)
A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
please specify the type of institution:
(k)
Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.
Ownership
(a)
Amount beneficially owned:
See response to Item 9 on each cover page.
(b)
Percent of class:
See response to Item 11 on each cover page.
(c)
Number of shares as to which the person has:
(i) Sole power to vote or to direct the vote:
See response to Item 5 on each cover page.
(ii) Shared power to vote or to direct the vote:
See response to Item 6 on each cover page.
(iii) Sole power to dispose or to direct the disposition of:
See response to Item 7 on each cover page.
(iv) Shared power to dispose or to direct the disposition of:
See response to Item 8 on each cover page.
The securities disclosed herein as potentially beneficially owned by Millennium Management LLC, Millennium Group Management LLC and Mr. Englander are held by entities subject to voting control and investment discretion by Millennium Management LLC and/or other investment managers that may be controlled by Millennium Group Management LLC (the managing member of Millennium Management LLC) and Mr. Englander (the sole voting trustee of the managing member of Millennium Group Management LLC). The foregoing should not be construed in and of itself as an admission by Millennium Management LLC, Millennium Group Management LLC or Mr. Englander as to beneficial ownership of the securities held by such entities.
Item 5.
Ownership of 5 Percent or Less of a Class.
Not Applicable
Item 6.
Ownership of more than 5 Percent on Behalf of Another Person.
Not Applicable
Item 7.
Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
Not Applicable
Item 8.
Identification and Classification of Members of the Group.
If a group has filed this schedule pursuant to §240.13d-1(b)(1)(ii)(K), so indicate under Item 3(k) and attach an exhibit stating the identity and Item 3 classification of each member of the group. If a group has filed this schedule pursuant to §240.13d-1(c) or §240.13d-1(d), attach an exhibit stating the identity of each member of the group.
See Exhibit I
Item 9.
Notice of Dissolution of Group.
Not Applicable
Item 10.
Certifications:
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
Integrated Core Strategies (US) LLC
Signature:
/s/ Gil Raviv
Name/Title:
Gil Raviv, Global General Counsel
Date:
03/27/2026
Millennium Management LLC
Signature:
/s/ Gil Raviv
Name/Title:
Gil Raviv, Global General Counsel
Date:
03/27/2026
Millennium Group Management LLC
Signature:
/s/ Gil Raviv
Name/Title:
Gil Raviv, Global General Counsel
Date:
03/27/2026
Israel A. Englander
Signature:
/s/ Israel A. Englander
Name/Title:
Israel A. Englander
Date:
03/27/2026
Comments accompanying signature: ** INTEGRATED CORE STRATEGIES (US) LLC
By: Integrated Holding Group LP, its Managing Member
By: Millennium Management LLC, its General Partner
Exhibit Information
Exhibit I: Joint Filing Agreement, dated as of March 27, 2026, by and among Integrated Core Strategies (US) LLC, Millennium Management LLC, Millennium Group Management LLC and Israel A. Englander.
